DDrare: Database of Drug Development for Rare Diseases

Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2% sodium chondroitin sulfate; 5% lidocaine/5 mg/ml 0.02% estradiol compound cream; AGN 203818; AQX-1125; AQX-1125 100 mg; AQX-1125 200 mg; ASP3652; ASP6294; Adalimumab; Alkalinized Lidocaine-Heparin; Amitriptyline; BOTOX 200U in normal saline; Bladder Instillations; Bladder instillation WITH triamcinolone acetonide; Bladder instillation WITHOUT triamcinolone acetonide; Bladder instillation with heparin/ lidocaine; Botox; Botulinum toxin A; Buckwheat; Bupivacaine; CICLOSPORIN; Cannabidiol; Cannabidiol vaginal suppository; Capsaicin; Certolizumab pegol; Chondroitin sulfate; Ciclosporin; Ciklosporin; Combination Product: Hyperbaric Oxygen Therapy-; Cyclosporine; DMSO; DMSO cocktail; Device: Intermittent Exposure to Oxygen via Oro-Nasal Mask; Device: interferential current; Dexmedetomidine; Dimethyl sulfoxide; ERB-041; Estradiol; Fospropofol; Fospropofol (Lusedra®) 10; Fospropofol (Lusedra®) 12; Fospropofol (Lusedra®) 6.5; Fremanezumab; Gefapixant; Glycine; Gralise; Heparin; Heparin & Alkalinized Lidocaine Bladder Instillation; Hyaluronic Acid and Chondroitin Sulfate; Hyaluronic acid; Hyaluronic acid/chondroitin sulfate; Hydrogen; IC Cocktail; IPD® (Japanese tradename); IPD® (suplatast tosilate); Intravesical onabotulinumtoxinA injection; JNJ-42160443; KRP-116D; Ketorolac; Ketorolac Tromethamine; LP-08 20mg; LP-08 80mg; LiRIS 400 mg; LiRIS low dose and LiRIS high dose; LiRIS®; LiRIS® 400 mg; Lidocaine; Lidocaine Releasing Intravesical System - LiRIS®; Liposome encapsulated BoNT-A; Liposomes; Low-dose naltrexone; MMF; MN-001; MN-001 BID; MR-MC-01; Metoprolol; Metoprolol Tartrate Oral Tablet; Mirabegron; Mycofenolate Mofetil (MMF); Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; NALOXONE HYDROCHLORIDE; Naloxone; Naltrexone; Normal Saline; Normal saline; Normal saline instillation; Nortriptyline; OXN 10/5 mg PR; OXN 20/10 mg PR; OXN 5/2.5 mg PR; OXYCODONE HYDROCHLORIDE; Omalizumab; Onabotulinum Toxin A; Onabotulinumtoxin A; OnabotulinumtoxinA; Other: Hyperbaric Oxygen Therapy; Other: Normal Saline; Other: Saline as a nasal spray; Other: inactive drug; Other: normal saline; Oxycodone; Oxycodone naloxone prolonged release tablets; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Oxygen; Oxytocin; PD 0299685; PD 0299685 at 15mg BID; PD 0299685 at 30mg BID; PD-0299685; PF-04383119; Pentosan polysulfate; Pentosan polysulfate sodium 100 mg; Placebo; Platelet enriched plasma; Platelet-Rich Plasma; Procedure: Pelvic Floor Physical Therapy; Procedure: Sham Cystoscopy Procedure; Procedure: Urodynamic study; Procedure: injections on posterior bladder wall excluding the trigone; Procedure: injections upper aspect of trigone of urinary bladder; Prograf; Propiverine; Propiverine Hydrochloride; RIMSO 50; RN624, RI624; Rimso 50; SANDIMMUN; SI-722; Sandimmun Neoral; Sildenafil; Sulfate; Suplatast tosilate; TACROLIMUS; TTI-1612; Tacrolimus; Tanezumab; Targinact 10 mg/5 mg prolonged-release tablets; Targinact 20mg/10 mg prolonged-release tablets; Targinact 5mg/2.5 mg prolonged-release tablets; Tramadol; Triamcinolone; Tromethamine; URG101; Water; YM672; YM672 (IPD®)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-004495-30-FI (EUCTR)	14/12/2015	20/10/2015	Safety of intravesical bladder instillations among patients with severe interstitial cystitis	Safety of intravesical bladder instillations among patients with severe interstitial cystitis	Interstitial cystitis and bladder pain syndrome MedDRA version: 18.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 18.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]	Trade Name: SANDIMMUN INN or Proposed INN: CICLOSPORIN	Oulu University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Finland
2	NCT01990898 (ClinicalTrials.gov)	November 2013	18/11/2013	Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action	Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action	Interstitial Cystitis	Drug: Cyclosporine	The Cleveland Clinic	NULL	Completed	18 Years	80 Years	All	26	Phase 2	United States
3	EUCTR2005-000890-23-SE (EUCTR)	13/10/2005	02/08/2005	NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine.	NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine.	Interstitiell cystit	Trade Name: Sandimmun Neoral Product Name: Sandimmun Neoral INN or Proposed INN: Ciklosporin	Ingrid Ehrén	NULL	Not Recruiting			Female: yes Male: yes	15		Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2015-004495-30-FI
(EUCTR)

14/12/2015

20/10/2015

Safety of intravesical bladder instillations among patients with severe interstitial cystitis

Interstitial cystitis and bladder pain syndrome
MedDRA version: 18.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 18.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]

Trade Name: SANDIMMUN
INN or Proposed INN: CICLOSPORIN

Oulu University Hospital

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Finland

NCT01990898
(ClinicalTrials.gov)

November 2013

18/11/2013

Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action

Interstitial Cystitis

Drug: Cyclosporine

The Cleveland Clinic

NULL

Completed

18 Years

80 Years

All

Phase 2

United States

EUCTR2005-000890-23-SE
(EUCTR)

13/10/2005

02/08/2005

NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine.

Interstitiell cystit

Trade Name: Sandimmun Neoral
Product Name: Sandimmun Neoral
INN or Proposed INN: Ciklosporin

Ingrid Ehrén

NULL

Not Recruiting

Female: yes
Male: yes

Sweden